CD19 and precursor B-cell acute lymphoblastic leukemia: In this study, MBMA was used to establish a survival model of anti-CD19 CAR T-cell therapy for B-ALL and quantitatively analyze the distribution characteristics of different co-stimulatory structural domains on survival data and their influencing factors, with the aim of providing reliable quantitative information for anti-CD19 CAR T-cell therapy for B-ALL.